Safety and Completion of Prophylactic Treatment for Latent Tuberculosis Infection in Children

Author:

Wang Yi1,Niu Yayan1,Zhang Jianping1,Ye Zhijian1,Wu Meiying1,Yu Xin1

Affiliation:

1. The Affiliated Infectious Disease Hospital of Soochow University

Abstract

Abstract

Background To investigate the safety and completion rate of prophylactic treatment for latent tuberculosis infection (LTBI) in children. Methods Patients who met the diagnostic criteria for LTBI and voluntarily accepted prophylactic treatment were enrolled from the outpatient department of Suzhou Fifth People’s Hospital from January 1, 2018, to February 28, 2021. According to age, participants were divided into a children's group (≤ 14 years old, 84 cases) and a teenage and adult group (> 14 years old, 69 cases). Depending on the different prophylactic treatment regimens, the completion rate and incidence of adverse drug reactions were compared between the different treatment groups. Results Close contact history with a pulmonary tuberculosis patient and malnutrition were the main risk factors for LTBI in children. The incidence of adverse drug reactions among children receiving prophylactic treatment was not higher than that among teenagers and adults, and 3 months isoniazid and rifapentine (3HP), 3 months isoniazid and rifampin (3HR), and 4 months rifampin (4R) regimens had better completion rate. However, the 3HP and 3HR regimens had a greater number of adverse drug reactions, especially the 3HR regimen. Only one patient progressed to active tuberculosis within 2 years of prophylactic treatment. Conclusion The 3HP, 3HR, and 4R regimens showed higher completion rates in children with LTBI, while the 4R and 3HP regimens demonstrated better safety. Preventive treatment can significantly reduce the risk of progression from LTBI to active tuberculosis in children.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3